Exogenous proteases confer a significant chemopreventive effect in experimental tumor models

Integrative Cancer Therapies

Volumn 7, Issue 4, 2008, Pages 295-310

  Wald, Martin ^a  

^a CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Breast; Chemoprevention; Lewis lung cancer; Melanoma; Pancreas; Protease

Indexed keywords

BREAST CANCER; CANCER RESEARCH; CARCINOGENESIS; CHEMOPROPHYLAXIS; ENZYME THERAPY; HUMAN; LEWIS CARCINOMA; MELANOMA; PANCREAS CANCER; PRIORITY JOURNAL; REVIEW; TUMOR MODEL;

ANIMALS; CHEMOPREVENTION; COMPLEMENTARY THERAPIES; HUMANS; NEOPLASM METASTASIS; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; PEPTIDE HYDROLASES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 58149177390     PISSN: 15347354     EISSN: 1552695X     Source Type: Journal    
DOI: 10.1177/1534735408327036     Document Type: Review

References (75)

1. Zänker KS Chemoprevention of cancer for the next millennium-quo vadis ? Cancer Lett. 1999 ; 143 (suppl 1). S7 - S11.
2. Secor ER, Jr, Carson WF, Cloutier MM, et al. Bromelain exerts anti-inflammatory effects in an ovalbumin-induced murine model of allergic airway disease. Cell Immunol. 2005 ; 237: 68-75.
3. Mahadeva R., Sharples L., Ross-Russell RI, Webb AK, Bilton D., Lomas DA Association of alpha(1)-antichymotrypsin deficiency with milder lung disease in patients with cystic fibrosis. Thorax. 2001 ; 56: 53-58.
4. Nadkarni KM The Indian Materia Medica. Mumbai, India: Popular Prakashan ; 1927.
5. Peckolt T., Peckolt G. Historia das Plantas Medicinaes e Utesi do Brazil. Rio de Janeiro ; 1988. Cited by Asenjo CF. J Am Pharm Assoc. 1940 ; 29: 8.
6. Beard J. The Enzyme Treatment of Cancer and Its Scientific Basis. London, UK: Chatto & Windus ; 1911.
7. Freund E., Kaminer G. Biochemische Grundlagen der Disposition für Karzinom. Wien, Germany: Julius Springer ; 1925.
8. Klaschka F. Oral Enzymes-New Approach to Cancer Treatment. Munich, Germany: Forum Medizin ; 1996.
9. Anderson AF, Schloss OM Allergy to cow's milk in infants with nutritional disorders. Am J Dis Child. 1923 ; 26: 415.
10. Baker A. Acne vulgaris. Treatment with oral bromelain (protease) and parenteral Staphyloccocus antigen. Pa Med J. 1962.
11. Barrett AJ, Salvesen G. Proteinase Inhibitors. Amsterdam, the Netherlands: Elsevier ; 1986.
12. Barrett AJ, Starkey PM The interaction of alpha2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanisms. Biochem J. 1973 ; 133: 709-724.
13. Barsom S., Sasse-Rollenhagen K., Bettermann A. Erfolgreiche Prostatitisbehandlung mit hydrolytischen Enzymen. Erfahrungsheilk. 1982 ; 31: 2.
14. Barsom S., Sasse-Rollenhagen K., Bettermann A. Zur Behandlung von Zystitiden und Zystopyelitiden mit hydrolytischen Enzymen. Acta Med Empir. 1983 ; 32: 125.
15. Martin GJ Clinical Enzymology. Boston, MA: Little, Brown ; 1958.
16. Jancsó N. Inflammation and inflammatory mechanisms. J Pharm Pharmacol. 1961 ; 13: 577-594.
17. Moss JN, Beiler JM, Martin GJ Effect of trypsin on levels of antibiotics in the spinal fluid. Bact Proc. 1955 ; 80.
18. Neubauer R. A plant protease for potentiation of and possible replacement of antibiotics. Exp Med Surg. 1961 ; 19: 143-160.
19. Rapoport C. The use of trypsin in the therapy of tuberculous lymphadenitis and tuberculous fistulae. Chest. 1958 ; 34: 154-161.
20. Rapoport C. A case report of miliary tuberculosis and tuberculous meningitis treated with trypsin and antibiotics: one-year follow-up. Del Med J. 1958 ; 30: 167-169.
21. Thompson IM, Schneider J., Lantin P. Trypsin therapy in genitourinary inflammations. Am Pract Dig Treat. 1958 ; 9: 1113-1114.
22. Steffen C., Menzel J. Basic studies on enzyme therapy of immune complex diseases. Wien Klin Wochenschr. 1985 ; 12: 376-385.
23. Kolac C., Streichhan P., Lehr CM Oral bioavailability of proteolytic enzymes. Eur J Pharm Biopharm. 1996 ; 42: 222-232.
24. Stauder G., Streichhahn P., Steffen C. Enzymtherapie-eine Bestandsaufnahme. Natur Ganzheitsmed. 1988 ; 1: 68-69.
25. Castell JV, Friedrich G., Kuhn CS, Poppe GE Intestinal absorption of undegraded proteins in men: presence of bromelain in plasma after oral intake. Am J Physiol. 1997 ; 273: 139-146.
26. James K. Interactions between cytokines and alpha2-macroglobulin. Immunol Today. 1990 ; 11: 163-166.
27. Heumann D., Vischer TL Immunomodulation by alpha 2-macroglobulin and alpha 2-macroglobulin-proteinase complexes: the effect on the human T lymphocyte response. Eur J Immunol. 1988 ; 18: 755-760.
28. Veremeenko KN, Dosenko VE, Kizim AI, Terzov AI The mechanisms of the curative action of systemic enzyme therapy. Lik Sprava. 2000 ;(2). 3-11.
29. Donath F., Roots I., Mai I., et al. Dose-related bioavailability of bromelain and trypsin after repeated oral administration. Eur J Clin Pharmacol. 1997 ; 52 (suppl): 146.
30. Uhlenbruck G. Sport, Alter und Immunsystem. Med Welt. 1993 ; 44: 303-308.
31. Emeis JJ, Brouwer A., Barelds J., Horan MA, Durham SK, Kooistra T. On the fibrinolytic system in aged rats, and its reactivity to endotoxin and cytokines. Thromb Haemost. 1992 ; 6: 697-701.
32. Klaschka F. Neue Perspektiven in der Tumortherapie. Grafelfing, Germany: Forum Medizin ; 1996: 105-106.
33. Hale LP, Haynes BF Bromelain treatment of human T cells removes CD44, CD45RA, E2/MIC2, CD6, CD7, CD8, and Leu8/ LAM1 surface molecules and markedly enhances D2-mediated T cell activation. J Immunol. 1992 ; 149: 3809-3816.
34. Harrach T., Gebauer F., Eckert K., Kunze R., Maurer H. Bromelain proteinases modulate CD44 expression on human Molt 4/8 leukaemia and SK-Mel 28 melanoma cells in vitro. Int J Oncol. 1994 ; 5: 485-488.
35. LaMarre J., Wollenberg GK, Gonias SL, Hayes MA Cytokine binding and clearance properties of proteinase-activated alpha 2-macroglobulins. Lab Invest. 1991 ; 65: 3-14.
36. Lehmann PV Immunomodulation by proteolytic enzymes. Nephrol Dial Transplant. 1996 ; 11: 952-955.
37. Sy MS, Lu D., Kogerman P., Culp LA Potential of targeting cell surface CD44 proteins with proteinases in preventing tumor growth and metastasis. Int J Immunother. 1997 ; 3/4: 105-109.
38. Desser L., Holomanova D., Zavadova E., Pavelka K., Mohr T., Herbacek I. Oral therapy with proteolytic enzymes decreases excessive TGF-β levels in human blood. Cancer Chemother Pharmacol. 2001 ; 47 (suppl): S10 - S15.
39. Heidland A., Sebekova K., Paczek L., Teschner M., Dammrich J., Gaciong Z. Renal fibrosis: role of impaired proteolysis and potential therapeutic strategies. Kidney Int. 1997 ; 62 (suppl): S32 - S35.
40. Lauer D., Müller R., Cott C., Otto A., Naumann M., Birkenmeier G. Modulation of growth factor binding properties of α2-macroglobulin by enzyme therapy. Cancer Chemother Pharmacol. 2001 ; 47 (suppl): S4 - S9.
41. Lauer D., Reichenbach A., Birkenmeier G. Alpha 2-macroglobulin-mediated degradation of amyloid beta 1-42: a mechanism to enhance amyloid beta catabolism. Exp Neurol. 2001 ; 167: 385-392.
42. Leskovar P., Zanon R., Nachbar F., Meschik K. Zirkulierende Immunkomplexe: Immunsuppressive Wirkung auf Monozyten und NK- Zellen und deren partielle Aufhebung durch hydrolytische Enzyme. Dtsch Zschr Onkol. 1993 ; 25: 12-18.
43. Kunze R., Ransberger K., Stauder G., Gebauer F. Proteolytic enzymes modulate the C1q-binding capacity of fixed immunocomplexes in vitro. Eur J Immunol Dis. 1996 ; 1 (suppl): 17-29.
44. Steffen C., Menzel J. In vivo degradation of immune complexes in the kidney by orally administered enzymes. Wien Klin Wochenschr. 1987 ; 99: 525-531.
45. Olejar T., Nouza K. Thrombin and trypsin receptors: the same mechanism of signalling on cellular surfaces. Bratisl Lek Listy. 1999 ; 100: 75-79.
46. Dery O., Corvera C., Steinhoff M., Bunnett NW Proteinase-activated receptors: novel mechanisms of signaling by serine proteases. Am J Physiol. 1998 ; 274: 1429-1452.
47. Sobey CG, Cocks TM Activation of protease-activated receptor-2 (PAR2) elicits nitric oxide-dependent dilatation of the basilar artery in vitro. Stroke. 1998 ; 29: 1439-1444.
48. Emilsson K., Wahlestedt C., Sun MK, Nystedt S., Owman C., Sundelin J. Vascular effect of proteinase-activated receptor 2 agonist peptide. J Vasc Res. 1997 ; 34: 267-272.
49. Evev-Eam S., Uziely B., Cohen P., et al. Thrombin receptor overexpression in malignant and physiological invasion processes. Nat Med. 1998 ; 4: 909-914.
50. Kong W., McConalogue K., Khitin LM, et al. Luminal trypsin may regulate enteroctes through proteinase activated receptor 2. Proc Natl Acad Sci USA. 1997 ; 94: 8884-8889.
51. Mari B., Guerin S., Far DF, et al. Thrombin and trypsin induced Ca(2+) mobilization in human T cell lines through interaction with different proteinase activated receptors. FASEB J. 1996 ; 10: 309-316.
52. Trevani AS, Andonegui G., Giordano M., et al. Neutrophil apoptosis induced by proteolytic enzymes. Lab Invest. 1996 ; 74: 711-721.
53. McLean PG, Aston D., Sarkar D., Ahluwalia A. Protease-activated receptor-2 activation causes EDHF-like coronary vasodilation: selective preservation in ischemia/reperfusion injury: involvement of lipoxygenase products, VR1 receptors, and C-fibers. Circ Res. 2002 ; 90: 465-472.
54. Heidland A., Sebekova K., Schinzel R. Advanced glycation end products and the progressive course of renal disease. Am J Kidney Dis. 2001 ; 38 (suppl 1). S100 - S106.
55. Xiang G., Schinzel R., Simm A., Sebekova K., Heidland A. Advanced glycation end products impair protein turnover in LLC-PK1: amelioration by trypsin. Kidney Int. 2001 ; 78 (suppl): S53 - S57.
56. Xiang G., Schinzel R., Simm A., et al. Advanced glycation end products (AGEs)-induced expression of TGF-β1 is suppressed by a protease in the tubule cell line LLC-PK1. Nephrol Dial Transplant. 2001 ; 16: 1562-1567.
57. Stopper H., Schinzel R., Sebeková K., Heidland A. Genotoxicity of advanced glycation end products in mammalian cells. Cancer Lett. 2003 ; 190: 151-156.
58. Luerti M., Vignali ML Influence of bromelain on penetration of antibiotics in uterus, salpinx and ovary. Drugs Expt Clin Res. 1978 ; 4: 45-48.
59. Tinozzi S., Venegoni A. Effect of bromelain on serum and tissue levels of amoxycillin. Drugs Exp Clin Res. 1978 ; 4: 39-44.
60. Shibata HR, et al. Activity on cancers cells and distribution in tissue of anticancer drugs. Prog Antimicrob Anticancer Chemother. 1970 ; 2: 334-339.
61. Desser L., Rehberger A., Paukovits W. Proteolytic enzymes and amylase induce cytokine production in human peripheral blood mononuclear cells in vitro. Cancer Biother. 1994 ; 3: 253-263.
62. Desser L., Rehberger A., Kokron E., Paukovits W. Cytokine synthesis in human peripheral blood mononuclear cells after oral administration of polyenzyme preparations. Oncology. 1993 ; 50: 403-407.
63. Desser L., Rehberger A. Induction of tumor necrosis factor in human peripheral-blood mononuclear cells by proteolytic enzymes. Oncology. 1990 ; 6: 475-477.
64. Závadová E., Desser L., Mohr T. Stimulation of reactive oxygen species production and cytotoxicity in human neutrophils in vitro and after oral administration of a polyenzyme preparation. Cancer Biother. 1995 ; 10: 147-152.
65. Wald M., Olejár T., Poučková P., Zadinová M. The influence of proteinases on in vivo blastic transformation in rat species SD/IPCV with spontaneous lymphoblastic leukaemia. Br J Haematol. 1998 ; 102: 294.
66. Wald M., Závadová E., Poučková P., Zadinová M., Boubelík M. Polyenzyme preparation Wobe-Mugos E inhibits growth of solid tumors and development of experimental metastases in mice. Life Sci. 1997 ; 3: PL43 - PL48.
67. Wald M., Olejár T., Šebková V., Zadinová M., Boubelík M., Pou?ková P. Mixture of trypsin, chymotrypsin and papain reduces formation of metastases and extends survival time of C57Bl6 mice with syngeneic melanoma B16. Cancer Chemother Pharmacol. 2001 ; 47 (suppl): S16 - S22.
68. Wald M., Olejár T., Poučková P., Zadinová M. Proteinases reduce metastatic dissemination and increase survival time in C57Bl6 mice with Lewis lung carcinoma. Life Sci. 1998 ; 63: PL237 - PL243.
69. Wald M., Poučková P., Hloušková D., Altnerová M., Olejár T. The influence of trypsin, chymotrypsin and papain on the growth of human pancreatic adenocarcinoma transplanted to nu/nu mice. Eur J Cancer. 1999 ; 4 (suppl): 148.
70. Wald M., Šebková V., Österreicher J., Zadinová M., Poučková P. Proteinase administration reduces growth of human breast and pancreatic cancer in nude mice and diminishes expression of some tumorigenesis biomarkers. Int J Immunother. 2001 ; 2-4: 65-73.
71. Sakalová A., Bock PR, Dedík L., et al. Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother Pharmacol. 2001 ; 47 (suppl): S38 - S44.
72. Sakalova A., Desser L., Zavadova E., Holomanova D., Mohr T. Enzyme therapy improved remission time, soluble TNF-receptors and beta2-microglobulin concentration in chemotherapy treated multiple myeloma patients. Br J Haematol. 1998 ; 1: 353.
73. Desser L., Sakalová A., Závadová E., Holomanová D., Mohr T. Concentrations of soluble tumor necrosis factor receptors, β2-microglobulin, IL-6 and TNF in serum of multiple myeloma patients after chemotherapy and after combined enzyme + chemotherapy. Int J Immunother. 1997 ; 3/4: 121-130.
74. Zavadova E., Savary CA, Templin S., Verschraegen CF, Freedman RS Maturation of dendritic cells from ovarian cancer patients. Cancer Chemother Pharmacol. 2001 ; 4: 289-296.
75. Fields RC, Schoenecker JG, Hart JP, Hoffman MR, Pizzo SV, Lawson JH Protease-activated receptor-2 signaling triggers dendritic cell development. Am J Pathol. 2003 ; 6: 1817-1822.